Vismodegib CAS 879085-55-9

Deskripsyon Product:

Non pwodwi: Vismodegib CAS 879085-55-9

 

Sinonim:

2-Kloro-N-[4-kloro{-3-({2-piridinil)fenil]-4-(methylsulfonyl)benzamid;BROMO-1-NAPHTA

BenzaMide, 2-kloro-N-[{4-kloro{-3-({2-piridinil)fenil]-4-(Methylsulfonyl)-;

VisModegib (GDC-0449);

 

Pwopriyete Chimik ak Fizik

Aparans: Blan ak Off-Blan Solid

Esè: 99% +

Pwen bouyi: 561.6±50.0 degre

Pwen k ap fonn: 179-181 degre

Pwa molekilè: 421.3

Dansite: 1.440

Pka:10.72±0.70

Estabilite: Ki estab pou 2 ane soti nan dat achte jan yo apwovizyone. Solisyon nan DMSO oswa etanòl ka estoke nan -20 degre pou jiska 3 mwa.

 

Aplikasyon:

Vimodej targets SMO protein and inhibits Gli activation, thereby inhibiting downstream gene transcription and expression.For the treatment of locally progressive or metastatic basal cell carcinoma in adults who have recurred after surgery or are not well treated with surgery or radiotherapy; One of the most common skin cancers is basal cell carcinoma (BCC), which originates in the surface layer of the skin and does not cause pain to patients. The risk was greatest for skin diseases that were regularly exposed to the sun or ultraviolet light. The development and listing of Vimedji has brought good news to patients with BCC, and its clinical role is important and the target market is huge, and it has to grow into a "giant bomb" class (>$1 milya) dwòg nan tan kap vini an.

 

 

 

Si w enterese nan pwodwi nou yo oswa si w gen nenpòt kesyon, tanpri ou lib pou kontakte nou!

 

 

Pwodwi anba patant yo ofri pou rezon R & D sèlman. Sepandan, responsablite final la se sèlman nan achtè a.

Baj popilè: vismodegib cas 879085-55-9, manifaktirè, founisè, faktori, achte, nan stock

• On: Tricine CAS 5704-04-1
• Pwochen: Trametinib CAS 871700-17-3